Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2009

01.01.2009 | Original Article

Diagnostic value of PET/CT for the staging and restaging of pediatric tumors

verfasst von: Margit Kleis, Heike Daldrup-Link, Katherine Matthay, Robert Goldsby, Ying Lu, Tibor Schuster, Carole Schreck, Philip W. Chu, Randall A. Hawkins, Benjamin L. Franc

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this retrospective study was to compare the diagnostic value of 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography (18F-FDG PET)/CT versus 18F-FDG PET and CT alone for staging and restaging of pediatric solid tumors.

Methods

Forty-three children and adolescents (19 females and 24 males; mean age, 15.2 years; age range, 6–20 years) with osteosarcoma (n = 1), squamous cell carcinoma (n = 1), synovial sarcoma (n = 2), germ cell tumor (n = 2), neuroblastoma (n = 2), desmoid tumor (n = 2), melanoma (n = 3), rhabdomyosarcoma (n = 5), Hodgkin’s lymphoma (n = 7), non-Hodgkin-lymphoma (n = 9), and Ewing’s sarcoma (n = 9) who had undergone 18F-FDG PET/CT imaging for primary staging or follow-up of metastases were included in this study. The presence, location, and size of primary tumors was determined separately for PET/CT, PET, and CT by two experienced reviewers. The diagnosis of the primary tumor was confirmed by histopathology. The presence or absence of metastases was confirmed by histopathology (n = 62) or clinical and imaging follow-up (n = 238).

Results

The sensitivities for the detection of solid primary tumors using integrated 18F-FDG PET/CT (95%), 18F-FDG PET alone (73%), and CT alone (93%) were not significantly different (p > 0.05). Seventeen patients showed a total of 153 distant metastases. Integrated PET/CT had a significantly higher sensitivity for the detection of these metastases (91%) than PET alone (37%; p < 0.05), but not CT alone (83%; p > 0.05). When lesions with a diameter of less than 0.5 cm were excluded, PET/CT (89%) showed a significantly higher specificity compared to PET (45%; p < 0.05) and CT (55%; p < 0.05). In a sub-analysis of pulmonary metastases, the values for sensitivity and specificity were 90%, 14%, 82% and 63%, 78%, 65%, respectively, for integrated PET/CT, stand-alone PET, and stand-alone CT. For the detection of regional lymph node metastases, 18F-FDG PET/CT, 18F-FDG PET alone, and CT alone were diagnostically correct in 83%, 61%, and 42%. A sub-analysis focusing on the ability of PET/CT, PET, and CT to detect osseous metastases showed no statistically significant difference between the three imaging modalities (p > 0.05).

Conclusion

Our study showed a significantly increased sensitivity of PET/CT over that of PET for the detection of distant metastases but not over that of CT alone. However, the specificity of PET/CT for the characterization of pulmonary metastases with a diameter > 0.5 cm and lymph node metastases with a diameter of <1 cm was significantly increased over that of CT alone.
Literatur
1.
Zurück zum Zitat Ross JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer 1996;77:201–7.PubMedCrossRef Ross JA, Severson RK, Pollock BH, Robison LL. Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups. Cancer 1996;77:201–7.PubMedCrossRef
2.
Zurück zum Zitat Schöder H, Yeung HW, Larson SM. CT in PET/CT: essential features of interpretation. J Nucl Med 2005;46:13525–5. Schöder H, Yeung HW, Larson SM. CT in PET/CT: essential features of interpretation. J Nucl Med 2005;46:13525–5.
3.
Zurück zum Zitat Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality FDG-PET/CT for tumor staging solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357–68.PubMedCrossRef Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality FDG-PET/CT for tumor staging solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357–68.PubMedCrossRef
4.
Zurück zum Zitat Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–9.PubMed Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–9.PubMed
5.
Zurück zum Zitat Pauls S, Buck AK, Hohl K, Halter G, Hetzel M, Blumstein NM, et al. Improved non-invasive T-staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin 2007;46:9–14. quiz N1–2.PubMed Pauls S, Buck AK, Hohl K, Halter G, Hetzel M, Blumstein NM, et al. Improved non-invasive T-staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin 2007;46:9–14. quiz N1–2.PubMed
6.
Zurück zum Zitat Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med 2007;37:316–31.PubMedCrossRef Jadvar H, Connolly LP, Fahey FH, Shulkin BL. PET and PET/CT in pediatric oncology. Semin Nucl Med 2007;37:316–31.PubMedCrossRef
7.
Zurück zum Zitat Franzius C, Juergens KU, Schober O. Is PET/CT necessary in paediatric oncology? For Eur J Nucl Med Mol Imaging 2006;33:960–5.CrossRef Franzius C, Juergens KU, Schober O. Is PET/CT necessary in paediatric oncology? For Eur J Nucl Med Mol Imaging 2006;33:960–5.CrossRef
8.
Zurück zum Zitat McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR AM J Roentgenol 2006;184:1293–304. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR AM J Roentgenol 2006;184:1293–304.
9.
Zurück zum Zitat Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, et al. Positron emission tomography/computed tomography with (18) fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007;49:901–5.PubMedCrossRef Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, et al. Positron emission tomography/computed tomography with (18) fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Pediatr Blood Cancer 2007;49:901–5.PubMedCrossRef
10.
Zurück zum Zitat Franzius C, Juergens KU, Vormoor J. PET/CT with diagnostic CT in the evaluation of childhood sarcoma. AJR AM J Roentgenol 2006;186:581. author reply 581–2.PubMedCrossRef Franzius C, Juergens KU, Vormoor J. PET/CT with diagnostic CT in the evaluation of childhood sarcoma. AJR AM J Roentgenol 2006;186:581. author reply 581–2.PubMedCrossRef
11.
Zurück zum Zitat Bar-Sever Z, Keidar Z, Ben-Barak A, Bar-Shalom R, Postovsky S, Guralnik L, et al. The incremental value of (18) F-FDG PET/CT in pediatric malignancies. EUR J Nucl Med Mol Imaging 2007;34:628–9.CrossRef Bar-Sever Z, Keidar Z, Ben-Barak A, Bar-Shalom R, Postovsky S, Guralnik L, et al. The incremental value of (18) F-FDG PET/CT in pediatric malignancies. EUR J Nucl Med Mol Imaging 2007;34:628–9.CrossRef
12.
Zurück zum Zitat Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG avid lesions still needed? Radiology 2007;244:257–62.PubMedCrossRef Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy—is biopsy of FDG avid lesions still needed? Radiology 2007;244:257–62.PubMedCrossRef
13.
Zurück zum Zitat Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006;30:689–94.PubMedCrossRef Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006;30:689–94.PubMedCrossRef
14.
Zurück zum Zitat Rhodes MM, Delbeke D, Whitlock JA, Martin W, Kuttesch JF, Frangoul HA, et al. Utility of FDG PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006;28:300–6.PubMedCrossRef Rhodes MM, Delbeke D, Whitlock JA, Martin W, Kuttesch JF, Frangoul HA, et al. Utility of FDG PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006;28:300–6.PubMedCrossRef
15.
Zurück zum Zitat Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H, et al. Whole body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR AM J Roentgenol 2001;177:229–36.PubMed Daldrup-Link HE, Franzius C, Link TM, Laukamp D, Sciuk J, Jürgens H, et al. Whole body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR AM J Roentgenol 2001;177:229–36.PubMed
16.
Zurück zum Zitat Kauffman WM, Fletcher BD, Hanna SL, Meyer WH. MR imaging findings in recurrent primary osseous Ewing sarcoma. Magn Reson Imaging 1994;12:1147–53.PubMedCrossRef Kauffman WM, Fletcher BD, Hanna SL, Meyer WH. MR imaging findings in recurrent primary osseous Ewing sarcoma. Magn Reson Imaging 1994;12:1147–53.PubMedCrossRef
17.
Zurück zum Zitat Shah Syed GM, Naseer H, Usmani GN, Cheema MA. Role of iodine-131 MIBG scanning in the management of paediatric patients with neuroblastoma. Med Princ Pract 2004;13:196–200.PubMedCrossRef Shah Syed GM, Naseer H, Usmani GN, Cheema MA. Role of iodine-131 MIBG scanning in the management of paediatric patients with neuroblastoma. Med Princ Pract 2004;13:196–200.PubMedCrossRef
18.
Zurück zum Zitat Hahn K, Charron M, Shulkin BL. Role of MR imaging and iodine 123 MIBG scintigraphy in staging of pediatric neuroblastoma. Radiology 2003;227:908.PubMedCrossRef Hahn K, Charron M, Shulkin BL. Role of MR imaging and iodine 123 MIBG scintigraphy in staging of pediatric neuroblastoma. Radiology 2003;227:908.PubMedCrossRef
19.
Zurück zum Zitat De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23–32.PubMedCrossRef De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23–32.PubMedCrossRef
20.
Zurück zum Zitat Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871–5.PubMed Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002;43:871–5.PubMed
21.
Zurück zum Zitat Juergens KU, Weckesser M, Stegger L, Franzius C, Beetz M, Schober O, et al. Tumor staging using whole body high resolution 16-channel PET/CT: does additional low dose chest CT in inspiration improve the detection of solitary pulmonary nodules? Eur Radiol 2006;16:1131–7.PubMedCrossRef Juergens KU, Weckesser M, Stegger L, Franzius C, Beetz M, Schober O, et al. Tumor staging using whole body high resolution 16-channel PET/CT: does additional low dose chest CT in inspiration improve the detection of solitary pulmonary nodules? Eur Radiol 2006;16:1131–7.PubMedCrossRef
22.
Zurück zum Zitat Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575–81.PubMedCrossRef Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002;225:575–81.PubMedCrossRef
23.
Zurück zum Zitat Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole body F-18 fluorodeoxyglucose positron emission tomography in patient taking recombinant erythropoietin. Clin Nucl Med 2004;29:161–3.PubMedCrossRef Blodgett TM, Ames JT, Torok FS, McCook BM, Meltzer CC. Diffuse bone marrow uptake on whole body F-18 fluorodeoxyglucose positron emission tomography in patient taking recombinant erythropoietin. Clin Nucl Med 2004;29:161–3.PubMedCrossRef
24.
Zurück zum Zitat Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173–80.PubMed Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173–80.PubMed
25.
Zurück zum Zitat Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145–55. quiz 162–3.PubMed Abouzied MM, Crawford ES, Nabi HA. 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol 2005;33:145–55. quiz 162–3.PubMed
26.
Zurück zum Zitat Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61–77. quiz 150–1.PubMed Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61–77. quiz 150–1.PubMed
27.
Zurück zum Zitat Olson PN, Everson LI, Griffiths HJ. Staging of musculoskeletal tumors. Radiol Clin North Am 1994;32:151–62.PubMed Olson PN, Everson LI, Griffiths HJ. Staging of musculoskeletal tumors. Radiol Clin North Am 1994;32:151–62.PubMed
28.
Zurück zum Zitat Silberstein E, Saenger E, Tofe AJ, Alexander GW Jr, Park HM. Imaging of bone metastases with 99 mTc-Sn-EHDP (diphosphonate), 18F and skeletal radiography. Radiology 1973;107:551–5.PubMed Silberstein E, Saenger E, Tofe AJ, Alexander GW Jr, Park HM. Imaging of bone metastases with 99 mTc-Sn-EHDP (diphosphonate), 18F and skeletal radiography. Radiology 1973;107:551–5.PubMed
29.
Zurück zum Zitat Yeung HW, Grewal RK, Gonen M, Schöder H, Larson SM. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003;44:1789–96.PubMed Yeung HW, Grewal RK, Gonen M, Schöder H, Larson SM. Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med 2003;44:1789–96.PubMed
30.
Zurück zum Zitat Gelfand MJ, O’hara SM, Curtwright LA, Mclean JR. Pre-medication to block [(18)F] FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiology 2005;35:984–90.CrossRef Gelfand MJ, O’hara SM, Curtwright LA, Mclean JR. Pre-medication to block [(18)F] FDG uptake in the brown adipose tissue of pediatric and adolescent patients. Pediatr Radiology 2005;35:984–90.CrossRef
31.
Zurück zum Zitat Söderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propanolol. Eur J Nucl Med Mol Imaging 2007;34:1018–22.PubMedCrossRef Söderlund V, Larsson SA, Jacobsson H. Reduction of FDG uptake in brown adipose tissue in clinical patients by a single dose of propanolol. Eur J Nucl Med Mol Imaging 2007;34:1018–22.PubMedCrossRef
32.
Zurück zum Zitat Garcia CA, Van Nostrand D, Atkins F, Acio E, Butler C, Esposito G, et al. Reduction of brown fat 2-deoxy-2-[F-18]fluoro-d-glucose uptake by controlling environmental temperature prior to positron emission tomography scan. Mol Imaging Biol 2006;8:24–9.PubMedCrossRef Garcia CA, Van Nostrand D, Atkins F, Acio E, Butler C, Esposito G, et al. Reduction of brown fat 2-deoxy-2-[F-18]fluoro-d-glucose uptake by controlling environmental temperature prior to positron emission tomography scan. Mol Imaging Biol 2006;8:24–9.PubMedCrossRef
33.
Zurück zum Zitat Von Schulthess GK, Hany TF. Imaging and PET-PET/CT imaging. J Radiol 2008;89:438–47. quiz 448. Von Schulthess GK, Hany TF. Imaging and PET-PET/CT imaging. J Radiol 2008;89:438–47. quiz 448.
34.
Zurück zum Zitat Visvikis D, Costa DC, Croasdale I, Lonn AH, Bomanji J, Gacinovic S, et al. CT-based attenuation correction in the calculation of semi-quantative indices of [18] FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344–53.PubMed Visvikis D, Costa DC, Croasdale I, Lonn AH, Bomanji J, Gacinovic S, et al. CT-based attenuation correction in the calculation of semi-quantative indices of [18] FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344–53.PubMed
35.
Zurück zum Zitat Ay MR, Zaidi H. Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. Eur J Nucl Med Mol Imaging 2006;33:1301–13.PubMedCrossRef Ay MR, Zaidi H. Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET. Eur J Nucl Med Mol Imaging 2006;33:1301–13.PubMedCrossRef
36.
Zurück zum Zitat Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003;33:228–37.PubMedCrossRef Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography—clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003;33:228–37.PubMedCrossRef
37.
Zurück zum Zitat Vera P, Ouvrier MJ, Hapdey S, Thillays M, Pesquet AS, Diologent B, et al. Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging 2007;34:1943–52.PubMedCrossRef Vera P, Ouvrier MJ, Hapdey S, Thillays M, Pesquet AS, Diologent B, et al. Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET/CT in lymphoma? Eur J Nucl Med Mol Imaging 2007;34:1943–52.PubMedCrossRef
38.
Zurück zum Zitat Bunyaviroch T, Turkington TG, Wong TZ, Wilson JW, Colsher JG, Coleman RE. Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol 2008;10:107–13.PubMedCrossRef Bunyaviroch T, Turkington TG, Wong TZ, Wilson JW, Colsher JG, Coleman RE. Quantitative effects of contrast enhanced CT attenuation correction on PET SUV measurements. Mol Imaging Biol 2008;10:107–13.PubMedCrossRef
39.
Zurück zum Zitat Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 2003;33:166–79.PubMedCrossRef Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 2003;33:166–79.PubMedCrossRef
40.
Zurück zum Zitat Ahmadian A, Ay MR, Bidgoli JH, Sarkar S, Zaidi H. Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm. Eur J Nucl Med Mol Imaging 2008;5:3542–7. Ahmadian A, Ay MR, Bidgoli JH, Sarkar S, Zaidi H. Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm. Eur J Nucl Med Mol Imaging 2008;5:3542–7.
41.
Zurück zum Zitat Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003;44:732–8.PubMed Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003;44:732–8.PubMed
42.
Zurück zum Zitat Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005;46:283–91.PubMed Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med 2005;46:283–91.PubMed
43.
Zurück zum Zitat Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hǿjgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167–75.PubMedCrossRef Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hǿjgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167–75.PubMedCrossRef
44.
Zurück zum Zitat Kleinermann RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006;36(suppl):121–5.CrossRef Kleinermann RA. Cancer risks following diagnostic and therapeutic radiation exposure in children. Pediatr Radiol 2006;36(suppl):121–5.CrossRef
45.
Zurück zum Zitat Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005;46:608–13.PubMed Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med 2005;46:608–13.PubMed
Metadaten
Titel
Diagnostic value of PET/CT for the staging and restaging of pediatric tumors
verfasst von
Margit Kleis
Heike Daldrup-Link
Katherine Matthay
Robert Goldsby
Ying Lu
Tibor Schuster
Carole Schreck
Philip W. Chu
Randall A. Hawkins
Benjamin L. Franc
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-0911-1

Weitere Artikel der Ausgabe 1/2009

European Journal of Nuclear Medicine and Molecular Imaging 1/2009 Zur Ausgabe